Samer A. Al’Hadidi, MD, discusses social determinants and resources that can help patients receive chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma.
Samer A. Al'Hadidi, MD, MS
Hematologist/oncologist and assistant professor in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Arkansas for Medical Sciences.
Articles by Samer A. Al'Hadidi, MD, MS
Samer A. Al’Hadidi, MD, discusses the follow-up data for ciltacabtagene autoleucel in patients with multiple myeloma.
Samer A. Al’Hadidi, MD, discusses the importance of personalized medicine in patients with multiple myeloma.
Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.
Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with transplant-ineligible multiple myeloma.